Brenda Cooperstone's most recent trade in Senti Biosciences Inc. was a trade of 43,900 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 7, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Senti Biosciences Inc. | Brenda Cooperstone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 43,900 | 43,900 | - | - | Stock Option (Right to Buy) | |
Senti Biosciences Inc. | Brenda Cooperstone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2024 | 62,500 | 62,500 | - | - | Stock Option (Right to Buy) | |
Lexeo Therapeutics Inc. | Brenda Cooperstone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
Senti Biosciences Inc. | Brenda Cooperstone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 62,500 | 62,500 | - | - | Stock Option (Right to Buy) | |
Senti Biosciences Inc. | Brenda Cooperstone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) |